Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis
Biomolecules and Biomedicine · 01.05.2023 · 23 (3) · 364-375
DOI: 10.17305/bjbms.2022.8369 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 01.05.2023. Verfasst von Jiang Bai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Second Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Kidney Transplantation, Kidney Failure, Chronic. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recurrent glomerulonephritis after renal transplantation is the third most common cause of allograft loss, the most frequent of which is associated with IgA nephropathy (IgAN). This study aims to provide a systematic review of the risk factors associated with recurrent IgAN after renal transplantation. We searched English and Chinese databases, including PubMed, Embase, Web of Science, CNKI, and others, and included all case-control studies involving risk factors for recurrent IgAN after renal transplantation from the databases’ establishment to March 2022. Data were analyzed using the Stata 12.0. A total of 20 case–control studies were included in the meta-analysis, with 542 patients with recurrent IgAN and 1385 patients without recurrent IgAN. The results showed that donor age (standardized mean difference [SMD] -0.13 [95% CI -0.26, -0.001]; P = 0.048), patient age at transplantation (SMD -0.41 [95% CI -0.53, -0.29]; P < 0.001), time from diagnosis to end-stage renal disease (SMD -0.42 [95% CI -0.74, -0.10]; P = 0.010), previous transplantation (odds ratio [OR] 1.73 [95% CI 1.06, 2.81]; P = 0.027), living donor (OR 1.86 [95% CI 1.34, 2.58]; P < 0.001), related donor (OR 2.64, [95% CI 1.84, 3.79]; P < 0.001), tacrolimus use (OR 0.71 [95% CI 0.52, 0.98]; P = 0.035), basiliximab use (OR 0.39 [95% CI 0.27, 0.55]; P < 0.001), proteinuria (SMD 0.42 [95% CI 0.13, 0.71]; P = 0.005) and serum IgA level (SMD 0.48 [95% CI 0.27, 0.69]; P < 0.001) were associated with recurrent IgAN after renal transplantation. In general, tacrolimus and basiliximab use were protective factors against recurrent IgAN after renal transplantation, whereas donor age, patient age at transplantation, time from diagnosis to end-stage renal disease, previous transplantation, living donor, related donor, proteinuria, and serum IgA level were risk factors for recurrent IgAN after renal transplantation. Clinical decision making should warrant further consideration of these risk factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Second Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China.
- Shanxi Medical University, Taiyuan, Shanxi, China.
- Department of Nephrology, Shanxi Provincial People's Hospital (Fifth Hospital) of Shanxi Medical University, Taiyuan, Shanxi, China.
- Department of Urology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Zitieren
APA
Bai, J., Wu, Q., Chen, J., Zheng, Z., Chang, J., Wang, L., Zhou, Y., & Guo, Q. (2023). Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis. Biomolecules and Biomedicine, 23(3), 364-375. https://doi.org/10.17305/bjbms.2022.8369
Vancouver
Bai J, Wu Q, Chen J, Zheng Z, Chang J, Wang L, et al. Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis. Biomolecules and Biomedicine. 2023;23(3):364-375. doi:10.17305/bjbms.2022.8369
BibTeX
@article{Bai2023,
author = {Bai, Jiang and Wu, Qiong and Chen, Jing and Zheng, Zhifang and Chang, Jiarong and Wang, Liangliang and Zhou, Yun and Guo, Qiang},
title = {Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis},
journal = {Biomolecules and Biomedicine},
year = {2023},
volume = {23},
number = {3},
pages = {364--375},
doi = {10.17305/bjbms.2022.8369}
}
EUVIMED